Next Article in Journal
Emerging Trends of Nanomedicines in the Management of Prostate Cancer: Perspectives and Potential Applications
Previous Article in Journal
Innovative Drug Delivery Systems for Regenerative Medicine
Previous Article in Special Issue
The Path from Nasal Tissue to Nasal Mucosa on Chip: Part 2—Advanced Microfluidic Nasal In Vitro Model for Drug Absorption Testing
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Addressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System

Department Drug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88400 Biberach, Germany
*
Author to whom correspondence should be addressed.
Pharmaceutics 2024, 16(3), 296; https://doi.org/10.3390/pharmaceutics16030296
Submission received: 18 January 2024 / Revised: 5 February 2024 / Accepted: 16 February 2024 / Published: 20 February 2024

Abstract

Microphysiological systems (MPSs) are promising in vitro technologies for physiologically relevant predictions of the human absorption, distribution, metabolism, and excretion (ADME) properties of drug candidates. However, polydimethylsiloxane (PDMS), a common material used in MPSs, can both adsorb and absorb small molecules, thereby compromising experimental results. This study aimed to evaluate the feasibility of using the PDMS-based Emulate gut-on-chip to determine the first-pass intestinal drug clearance. In cell-free PDMS organ-chips, we assessed the loss of 17 drugs, among which testosterone was selected as a model compound for further study based on its substantial ad- and absorptions to organ chips and its extensive first-pass intestinal metabolism with well-characterized metabolites. A gut-on-chip model consisting of epithelial Caco-2 cells and primary human umbilical vein endothelial cells (HUVECs) was established. The barrier integrity of the model was tested with reference compounds and inhibition of drug efflux. Concentration–time profiles of testosterone were measured in cell-free organ chips and in gut-on-chip models. A method to deduce the metabolic clearance was provided. Our results demonstrate that metabolic clearance can be determined with PDMS-based MPSs despite substantial compound loss to the chip. Overall, this study offers a practical protocol to experimentally assess ADME properties in PDMS-based MPSs.
Keywords: microphysiological system (MPS); gut-on-chip; polydimethylsiloxane (PDMS); absorption, distribution, metabolism, and excretion (ADME) microphysiological system (MPS); gut-on-chip; polydimethylsiloxane (PDMS); absorption, distribution, metabolism, and excretion (ADME)

Share and Cite

MDPI and ACS Style

Carius, P.; Weinelt, F.A.; Cantow, C.; Holstein, M.; Teitelbaum, A.M.; Cui, Y. Addressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System. Pharmaceutics 2024, 16, 296. https://doi.org/10.3390/pharmaceutics16030296

AMA Style

Carius P, Weinelt FA, Cantow C, Holstein M, Teitelbaum AM, Cui Y. Addressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System. Pharmaceutics. 2024; 16(3):296. https://doi.org/10.3390/pharmaceutics16030296

Chicago/Turabian Style

Carius, Patrick, Ferdinand Anton Weinelt, Chris Cantow, Markus Holstein, Aaron M. Teitelbaum, and Yunhai Cui. 2024. "Addressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System" Pharmaceutics 16, no. 3: 296. https://doi.org/10.3390/pharmaceutics16030296

APA Style

Carius, P., Weinelt, F. A., Cantow, C., Holstein, M., Teitelbaum, A. M., & Cui, Y. (2024). Addressing the ADME Challenges of Compound Loss in a PDMS-Based Gut-on-Chip Microphysiological System. Pharmaceutics, 16(3), 296. https://doi.org/10.3390/pharmaceutics16030296

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop